Page 1 of 3

Metastatic renal-cell carcinoma: switch to metronomic chemotherapy could offer new treatment option

A new multi-targeted chemo-switch drug regimen shows promising anti-tumour activity with manageable side effects in patients with metastatic renal-cell carcinoma ( RCC ), a disease with few treatment options. Combining maximum tolerated dose ( MTD ) chemotherapy ( Gemcitabine; Gemzar ) with metronom...
Read Article

Advanced kidney cancer: Sorafenib shrinks tumor prior to surgery

Physicians who conducted a pilot study at University of North Carolina ( UNC ) Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug Sorafenib ( Nexavar ) can reduce the size of large kidney tumors and could be safely undertaken administered without adding significan...
Read Article

Advanced kidney cancer: Sunitinib shows promising results in patients with poor prognosis

Sunitinib ( Sutent ) prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer ( metastatic renal cell carcinoma ) patients with a poor prognosis such as the elderly and those whose cancer has spread to the brain. Sunitinib is an oral targeted drug t...
Read Article

Sorafenib improves progression free survival in patients with breast cancer

In the advanced breast cancer, one study has found that if Sorafenib ( Nexavar ) is combined with the chemotherapy drug, Capecitabine ( Xeloda ), it makes a significant difference to the time women live without their disease worsening. Results showed that patients who received Sorafenib plus Capec...
Read Article

Pazopanib in treating patients with aggressive thyroid cancer

Mayo investigators reported that cancer in about two-thirds of 37 patients with aggressive differentiated thyroid cancer treated with the drug Pazopanib ( Votrient ) either stopped growing, or quickly shrank. The patient responses are promising, the researchers say, because all patients had fast...
Read Article

Advanced kidney cancer: Sunitinib shows promising results in patients with poor prognosis

Sunitinib ( Sutent ) prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer ( metastatic renal cell carcinoma ) patients with a poor prognosis such as the elderly and those whose cancer has spread to the brain. Sunitinib is an oral targeted drug t...
Read Article

ODAC recommends against approving Tarceva for first-line maintenance use in advanced non-small cell lung cancer

OSI Pharmaceuticals and Genentech announced that FDA ( Food and Drug Administration ) Oncologic Drugs Advisory Committee ( ODAC ) voted 12 to one recommending against approval of Tarceva ( Erlotinib ) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer ( N...
Read Article

Advanced form of kidney cancer: Votrient approved

The FDA ( Food and Drug Administration ) has approved Votrient ( Pazopanib ), the sixth drug to be approved for kidney cancer since 2005. Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is i...
Read Article

Cancer: new biomarkers can predict response to treatments

Genetic variations ensure that no two people are exactly alike, nor are their cancers. Researchers now have the tools and the knowledge to predict how individuals will respond to cancer therapy, enabling more precise and effective treatment. At the 2008 Annual Meeting of the American Association ...
Read Article

Treatment with RAD001 increases time without tumour growth in patients with advanced kidney cancer

Updated study findings from the RECORD-1 ( REnal Cell cancer treatment with Oral RAD001 given Daily ) study have shown that patients with advanced kidney cancer receiving RAD001 had no tumour growth for nearly 5 months versus 1.9 months for patients receiving placebo ( hazard ratio = 0.33; p< 0.001 ...
Read Article